- The increasing need for effective treatment options to manage acute viral outbreaks, postherpetic neuralgia (PHN), and associated neuropathic pain is boosting demand for antiviral agents, corticosteroids, and supportive pain therapies.
- The market benefits from ongoing R&D into next-generation vaccines and long-term postherpetic neuralgia management, public health awareness campaigns, and increased access to early diagnostic tools.
- North America is expected to dominate the herpes zoster drug market with a share of 41.31%, due to advanced healthcare infrastructure, the high adoption of cutting-edge localization technologies, and the strong presence of key market players
- For instance, the number of herpes zoster (shingles) cases reported in the U.S. has shown a steady increase over the past decade. From major hospitals to community clinics, the North America region not only administers treatments widely but also drives innovations in antiviral drug development for herpes zoster.
- Asia-Pacific is expected to be the fastest growing region in the herpes zoster drug market during the forecast period due to rapid improvements in healthcare facilities, increasing awareness about herpes zoster, and the rising number of patients seeking treatment.
- The antiviral drugs segment is expected to dominate the market with a market share of 38.65% due to its role in directly addressing the underlying viral infection. Symptomatic treatments and pain management therapies are also significant segments, providing relief from associated symptoms such as rash and neuropathic pain, but antiviral therapy continues to be the cornerstone of effective herpes zoster management.
